This is a news story, published by BGR, that relates primarily to Jemperli news.
For more Jemperli news, you can click here:
more Jemperli newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from BGR, you can click here:
more news from BGROtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
advanced rectal cancer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest advanced rectal cancer type news, cancer therapy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
advanced rectal cancersBGR
•80% Informative
A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center .
The study included 42 patients suffering from mismatch repair deficient (dMMR) locally advanced rectal cancer, a type of bowel cancer.
GSK presented the new data at the American Society of Clinical Oncology this week .
VR Score
78
Informative language
77
Neutral language
33
Article tone
formal
Language
English
Language complexity
62
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
3
Source diversity
2
Affiliate links
no affiliate links